Microsoft and NVIDIA expand collaboration in healthcare innovation

Microsoft and NVIDIA expand collaboration in healthcare innovation
Preview
Source: Pharmaceutical Technology
The partnership will aid in faster drug discovery. Credit: Elnur / Shutterstock.com.
Microsoft has announced plans to broaden its partnership with NVIDIA to leverage generative AI, cloud technology and accelerated computing to enhance healthcare and life sciences innovation.
The collaboration will merge Microsoft Azure’s global reach and advanced expertise with NVIDIA’s DGX Cloud and Clara computing platforms to spur innovation and improve patient outcomes.
The initiative will offer healthcare providers, pharmaceutical companies and medical device manufacturers opportunities to execute swift innovations in clinical research, drug discovery and care delivery.
The key features of the partnership include accelerated drug discovery with BioNeMo on NVIDIA’s DGX Cloud, hosted on Azure.
This approach will aid in expediting clinical research and drug discovery and boost access to precision therapies.
See Also:
Biotheus and Hansoh Pharmaceutical expand ADC collaboration
Microsoft and NVIDIA expand collaboration in healthcare innovation
Preview
Source: Pharmaceutical Technology
Microsoft and NVIDIA expand collaboration in healthcare innovation
Preview
Source: Pharmaceutical Technology
The collaboration will bolster clinical research and care delivery using imaging-based AI diagnostic technology through Azure, NVIDIA MONAI and the Nuance Precision Imaging Network.
The deal will also expedite genomics analysis with the SOPHiA DDM platform on Azure, powered by NVIDIA Parabricks.
Microsoft Health & Life Sciences corporate vice-president Peter Durlach stated: “Microsoft is building on its longstanding collaboration with NVIDIA to empower the healthcare and life sciences industry with the power of Azure and generative AI, helping unlock new horizons for clinical research, drug discovery and patient care worldwide.
“Through this collaboration, we aim to help the industry unlock breakthroughs in healthcare, making care more precise, accessible and effective to deliver a meaningful difference in the lives of patients globally.”
Cognizant is also advancing the application of generative AI technology with the NVIDIA BioNeMo platform to address drug discovery challenges in life sciences.
It seeks to enhance productivity in development and hasten the delivery of new treatments to the market.
By utilising generative AI technologies, clinical researchers, can quickly navigate vast datasets, predict drug compound interactions more accurately, and set out new drug development pathways.
Cognizant, with its deep expertise in life sciences and AI, aims to provide clients with access to BioNeMo’s pre-trained generative AI models, frameworks and application programming interfaces for rapid model training and customisation using proprietary data.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.